CYP2D6 pharmacogenomics of tamoxifen treatment.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003577:Cytochrome P-450 Enzyme System; D018795:Device Approval; D018572:Disease-Free Survival; D005260:Female; D005838:Genotype; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D010597:Pharmacogenetics; D017698:Postmenopause; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013629:Tamoxifen / Q000378:metabolism / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D003577:Cytochrome P-450 Enzyme System; D019389:Cytochrome P-450 CYP2D6